BCAX
Bicara Therapeutics Inc.
$18.48
-$0.37(-1.96%)
52
Overall
60
Value
63
Tech
34
Quality
Market Cap
$1.17B
Volume
2.09M
52W Range
$7.80 - $19.75
Target Price
$32.57
Company Overview
| Mkt Cap | $1.17B | Price | $18.48 |
| Volume | 2.09M | Change | -1.96% |
| P/E Ratio | -17.2 | Open | $18.97 |
| Revenue | -- | Prev Close | $18.85 |
| Net Income | $-68.0M | 52W Range | $7.80 - $19.75 |
| Div Yield | N/A | Target | $32.57 |
| Overall | 52 | Value | 60 |
| Quality | 34 | Technical | 63 |
No chart data available
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. The company's lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Latest News
Stifel Nicolaus Sticks to Its Buy Rating for Bicara Therapeutics Inc. (BCAX)
TipRanks Auto-Generated Intelligence Newsdesk•5 days ago
Wedbush Reaffirms Their Buy Rating on Bicara Therapeutics Inc. (BCAX)
TipRanks Auto-Generated Intelligence Newsdesk•5 days ago
3 ‘Strong Buy’ Stocks to Buy Today, 12/8/2025, According to Top Analysts
Shalu Saraf•6 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BCAX | $18.48 | -2.0% | 2.09M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Bicara Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW